Literature DB >> 16088803

More on RotaShield and intussusception: the role of age at the time of vaccination.

L Simonsen1, C Viboud, A Elixhauser, R J Taylor, A Z Kapikian.   

Abstract

BACKGROUND: RotaShield, a vaccine intended to prevent severe rotavirus diarrhea, was withdrawn in July 1999, 9 months after it became available in the United States, because of a temporal association with intussusception events that occurred in vaccinated infants. We explore here the effect of age on the risk of intussusception.
METHODS: We reanalyzed a case-control database of the Centers for Disease Control and Prevention by use of a 21-day window, to define vaccine-associated events. We obtained data on vaccine use from the National Immunization Survey and estimated the age-stratified background incidence of intussusception by use of Healthcare Cost and Utilization Project data. We combined these data to estimate how absolute risk varies with age and to model the projected population-attributable risk associated with 3 different vaccination schedules.
RESULTS: We found that the incidence of intussusception associated with the first dose of vaccine increased with age. Infants > or = 90 days old accounted for 80% of cases of intussusception associated with a first dose but had received only 38% of first doses. Modeling of the recommended schedule of vaccination at ages 2, 4, and 6 months projected 1 intussusception event/11,000-16,000 vaccine recipients; modeling of a 2-dose schedule beginning in the neonatal period projected 1 intussusception event/38,000-59,000 vaccine recipients.
CONCLUSIONS: The practice of initiating immunization after age 90 days, which we call "catch-up" vaccination, contributed disproportionately to the occurrence of intussusception associated with the use of RotaShield. A fully implemented 2-dose vaccination schedule begun during the neonatal period would lead to, at most, a 7% increase in the incidence of intussusception above the annual background incidence.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16088803     DOI: 10.1086/431512

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  31 in total

1.  Intussusception-associated hospitalisations in southern Germany.

Authors:  Lyn J Kohl; Andrea Streng; Veit Grote; Sibylle Koletzko; Johannes G Liese
Journal:  Eur J Pediatr       Date:  2010-07-17       Impact factor: 3.183

Review 2.  Overview of the Development, Impacts, and Challenges of Live-Attenuated Oral Rotavirus Vaccines.

Authors:  Olufemi Samuel Folorunso; Olihile M Sebolai
Journal:  Vaccines (Basel)       Date:  2020-06-27

3.  Trends in intussusception hospitalizations among US infants, 1993-2004: implications for monitoring the safety of the new rotavirus vaccination program.

Authors:  Jacqueline E Tate; Lone Simonsen; Cecile Viboud; Claudia Steiner; Manish M Patel; Aaron T Curns; Umesh D Parashar
Journal:  Pediatrics       Date:  2008-05       Impact factor: 7.124

4.  Rotavirus vaccine and intussusception.

Authors:  Stephan Foster
Journal:  J Pediatr Pharmacol Ther       Date:  2007-01

Review 5.  Rotavirus infections and vaccines: burden of illness and potential impact of vaccination.

Authors:  Keith Grimwood; Stephen B Lambert; Richard J Milne
Journal:  Paediatr Drugs       Date:  2010-08-01       Impact factor: 3.022

Review 6.  Vaccines against human diarrheal pathogens: current status and perspectives.

Authors:  Nathalie Böhles; Nathalie Böhles; Kim Busch; Kim Busch; Michael Hensel; Michael Hensel
Journal:  Hum Vaccin Immunother       Date:  2014-05-26       Impact factor: 3.452

Review 7.  Contributions and challenges for worldwide vaccine safety: The Global Advisory Committee on Vaccine Safety at 15 years.

Authors:  Edwin J Asturias; Melinda Wharton; Robert Pless; Noni E MacDonald; Robert T Chen; Nicholas Andrews; David Salisbury; Alexander N Dodoo; Kenneth Hartigan-Go; Patrick L F Zuber
Journal:  Vaccine       Date:  2016-05-16       Impact factor: 3.641

8.  Efficacy, immunogenicity, and safety of two doses of a tetravalent rotavirus vaccine RRV-TV in Ghana with the first dose administered during the neonatal period.

Authors:  George E Armah; Albert Z Kapikian; Timo Vesikari; Nigel Cunliffe; Robert M Jacobson; D Bruce Burlington; Leonard P Ruiz
Journal:  J Infect Dis       Date:  2013-04-18       Impact factor: 5.226

Review 9.  Rotaviruses: from pathogenesis to vaccination.

Authors:  Harry B Greenberg; Mary K Estes
Journal:  Gastroenterology       Date:  2009-05-07       Impact factor: 22.682

10.  Potential safety issues and other factors that may affect the introduction and uptake of rotavirus vaccines.

Authors:  N Aliabadi; J E Tate; U D Parashar
Journal:  Clin Microbiol Infect       Date:  2016-04-26       Impact factor: 8.067

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.